Edan Instruments Dokumenti
Dokumenti
0
Tiker
300206.SZ
ISIN
CNE100001252
Edan Instruments SEC Filings
Tips | Ziņojums | Datums |
|---|---|---|
| Nav pieejamu dokumentu | ||
Edan Instruments Dokumenti 2026
Šajā lapā atrodami visi oficiālie dokumenti un SEC faili Edan Instruments akciju (300206.SZ, ISIN: CNE100001252). Tas ietver gada pārskatus (10-K forma), ceturkšņa pārskatus (10-Q forma) un iekšējus darījumus (4. forma). Pašlaik ir pieejami 0 dokumenti. Dati tiek regulāri atjaunināti, lai investoriem sniegtu pilnīgu pārskatu par Edan Instruments normatīvo iesniegumiem.
Edan Instruments Akciju analīze
Edan Instruments Edan Instruments, Inc. generates revenue through the design, manufacture, and sale of medical equipment, including maternity product series like doppler fetal heart beat monitors, ultrasonic doppler fetal heart beat monitors, fetal/maternal monitors, and maternity integrated diagnostic monitoring systems. The company also sells electrocardiograph series such as digital twelve-channel electrocardiographs, digital six-channel electrocardiographs, and electrocardiographic workstations, along with monitoring products like portable multi-variable monitors and central monitoring systems. Additionally, Edan offers spare parts and in vitro diagnostics products to support its equipment and medical services. The primary buyers of Edan's products are healthcare institutions, including hospitals and clinics, which purchase medical devices for diagnostic and monitoring purposes. These institutions rely on Edan's maternity, electrocardiograph, and monitoring systems to provide patient care. The company's in vitro diagnostics products are also sold to medical facilities for laboratory testing needs. Edan's product segments are defined by medical equipment categories: maternity, electrocardiograph, monitoring, and ultrasonic image systems. The spare parts and in vitro diagnostics businesses complement these segments by providing essential accessories and diagnostic tools. Revenue is derived from direct sales of these products to healthcare providers, with no mention of third-party distribution or additional services beyond the described offerings.